432 related articles for article (PubMed ID: 8855293)
1. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
2. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
Timmerman JM; Levy R
J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
[TBL] [Abstract][Full Text] [Related]
5. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
7. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
10. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
11. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
Timmerman JM; Czerwinski DK; Davis TA; Hsu FJ; Benike C; Hao ZM; Taidi B; Rajapaksa R; Caspar CB; Okada CY; van Beckhoven A; Liles TM; Engleman EG; Levy R
Blood; 2002 Mar; 99(5):1517-26. PubMed ID: 11861263
[TBL] [Abstract][Full Text] [Related]
12. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity.
Levitsky HI; Montgomery J; Ahmadzadeh M; Staveley-O'Carroll K; Guarnieri F; Longo DL; Kwak LW
J Immunol; 1996 May; 156(10):3858-65. PubMed ID: 8621924
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
Coscia M; Mariani S; Battaglio S; Di Bello C; Fiore F; Foglietta M; Pileri A; Boccadoro M; Massaia M
Leukemia; 2004 Jan; 18(1):139-45. PubMed ID: 14574332
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
15. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
16. A genetic approach to idiotypic vaccination for B cell lymphoma.
Stevenson FK; Zhu D; King CA; Ashworth LJ; Kumar S; Thompsett A; Hawkins RE
Ann N Y Acad Sci; 1995 Nov; 772():212-26. PubMed ID: 8546396
[TBL] [Abstract][Full Text] [Related]
17. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
19. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines.
Hakim I; Levy S; Levy R
J Immunol; 1996 Dec; 157(12):5503-11. PubMed ID: 8955200
[TBL] [Abstract][Full Text] [Related]
20. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
